New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
04:55 EDTBMRN, BMRN, BMRN, BMRN, BMY, BMY, BMY, BMY, DNA, DNA, DNA, DNA, SNY, SNY, SNY, SNY, OVAS, OVAS, OVAS, OVAS, RHHBY, RHHBY, RHHBY, RHHBY, ADXS, ADXS, ADXS, ADXS, CPXX, CPXX, CPXX, CPXX, RARE, RARE, RARE, RARE, SGMO, SGMO, SGMO, SGMO, BLUE, BLUE, BLUE, BLUE, MRK, MRK, MRK, MRKBIO to hold a convention
BIO International Convention to be held in San Diego on June 23-26.
News For BMRN;BLUE;SGMO;RARE;CPXX;ADXS;RHHBY;OVAS;SNY;DNA;BMY;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
12:42 EDTMRKNY AG announces $31M Medicaid settlement with Organon
Subscribe for More Information
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:57 EDTMRK, BMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:51 EDTOVASOvaScience management to meet with Leerink
Meetings to be held on Los Angeles on October 21 and in San Diego on October 22 hosted by Leerink.
07:36 EDTADXSAdvaxis provides clinical update for Phase 1/2 trial of ADXS-HPV candidate
Subscribe for More Information
07:29 EDTSNYSelecta, JDRF, Sanofi extend collaboration for SVP immunotherapy
Subscribe for More Information
05:26 EDTSNYSanofi upgraded to Outperform from Neutral at Credit Suisse
October 14, 2014
11:23 EDTSNY, BMY, MRK, RHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
09:00 EDTSNYSanofi rotavirus vaccine enters Phase III trials in India
Subscribe for More Information
08:08 EDTSNYRegulus Therapeutics to present new preclinical data on multiple programs
Regulus Therapeutics (RGLS) announced that it will present new preclinical data on multiple programs and an overview of its clinical portfolio at the 10th Annual Oligonucleotide Therapeutics Society meeting being held October 12-October 15 at the Hilton San Diego Resort and Spa. In a poster titled "Anti-Diabetic Activity of miR-103/107 Anti-miRs", Regulus scientists will present preclinical data further demonstrating the potential benefit of a microRNA therapeutic for the treatment of metabolic disorders. In a poster titled "Inhibition of miR-21 with RG-012 Improves Renal Function and Survival in Multiple Strains of Col4A3 Deficient Mice", Regulus scientists, in collaboration with its strategic alliance partner Sanofi (SNY), will present new preclinical data demonstrating that weekly subcutaneous delivery of RG-012 has shown to provide both glomerular and tubule protection in the kidneys of Col4A3 deficient mice in an Alport syndrome model.
07:04 EDTBLUEbluebird bio says first patient with sicle cell disease undergoes infusion
Subscribe for More Information
October 13, 2014
09:11 EDTRAREUltragenyx announces interim data from Phase 2 study
Subscribe for More Information
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:37 EDTMRKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
October 10, 2014
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
October 9, 2014
08:32 EDTMRKMerck HCV solutions becoming more credible, says Bernstein
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use